SZUKF Stock Chart & Stats
$32.03
$0.00(0.00%)
At close: 4:00 PM EDT
$32.03
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$27.38 - $45.30
Previous CloseN/A
Volume2.00
Average Volume (3M)0.00
Market Cap
$1.90B
Enterprise Value$209.64K
Total Cash (Recent Filing)$148.78B
Total Debt (Recent Filing)$24.38B
Price to Earnings (P/E)9.8
Beta0.13
Next Earnings
Nov 06, 2026EPS Estimate
0.55Next Dividend Ex-DateN/A
Dividend Yield2.48%
Share Statistics
EPS (TTM)542.90
Shares Outstanding72,167,206
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)1.00
Price to Sales (P/S)0.17
P/FCF Ratio22.42
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$40.64Price Target Upside26.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)2.33
Revenue Forecast (FY)$16.18B
Bulls Say, Bears Say
Bulls Say
Steady Revenue GrowthSustained revenue expansion supports the durability of Suzuken's pharmaceutical distribution franchise. Continued demand from hospitals, clinics, and pharmacies can provide a stable operating base, even though growth is moderate rather than rapid.
Improving ProfitabilityImproved profitability indicates better earnings power and potential benefits from product mix, pricing, or operating efficiency. If maintained, the progress can strengthen internal funding capacity in a structurally low-margin wholesale business.
Very Conservative Balance SheetMinimal leverage materially reduces financial risk and interest burden, giving Suzuken flexibility to withstand industry pressure, fund logistics capabilities, and support customers without relying heavily on external financing.
Bears Say
Volatile Cash ConversionLarge year-to-year cash-flow swings reduce confidence in earnings conversion and may reflect significant working-capital needs in pharmaceutical distribution. Recurring inventory or receivables volatility could constrain reinvestment and shareholder returns.
Persistently Thin MarginsThe low-margin wholesale model leaves limited room to absorb supplier-cost increases, logistics inflation, or competitive pricing pressure. Small changes in operating efficiency can therefore have a meaningful effect on long-term profitability.
Recent EBIT PressureA decline in EBIT alongside revenue growth suggests that incremental sales are not currently translating fully into operating profit. If cost pressure persists, it could slow the profitability improvement that has supported Suzuken's recent financial progress.
SZUKF FAQ
What was Suzuken Co Ltd’s price range in the past 12 months?
Suzuken Co Ltd lowest stock price was $27.38 and its highest was $45.30 in the past 12 months.
What is Suzuken Co Ltd’s market cap?
Suzuken Co Ltd’s market cap is $1.90B.
When is Suzuken Co Ltd’s upcoming earnings report date?
Suzuken Co Ltd’s upcoming earnings report date is Nov 06, 2026 which is in 49 days.
How were Suzuken Co Ltd’s earnings last quarter?
Suzuken Co Ltd released its earnings results on Aug 07, 2026. The company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.459 by -$0.139.
Is Suzuken Co Ltd overvalued?
According to Wall Street analysts Suzuken Co Ltd’s price is currently Undervalued.
Does Suzuken Co Ltd pay dividends?
Suzuken Co Ltd pays a Semiannually dividend of $0.384 which represents an annual dividend yield of 2.48%. See more information on Suzuken Co Ltd dividends here
What is Suzuken Co Ltd’s EPS estimate?
Suzuken Co Ltd’s EPS estimate is 0.55.
How many shares outstanding does Suzuken Co Ltd have?
Suzuken Co Ltd has 72,167,206 shares outstanding.
What happened to Suzuken Co Ltd’s price movement after its last earnings report?
Suzuken Co Ltd reported an EPS of $0.32 in its last earnings report, missing expectations of $0.459. Following the earnings report the stock price went up 0.872%.
Which hedge fund is a major shareholder of Suzuken Co Ltd?
Currently, no hedge funds are holding shares in SZUKF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Suzuken Co Ltd
Suzuken Co., Ltd., along with its affiliated companies, operates primarily as a wholesale distributor of pharmaceuticals, serving both domestic and international markets. The company's diverse activities are organized into four distinct divisions. Its Pharmaceutical Distribution Business focuses on sourcing a wide array of products, including ethical drugs, diagnostic reagents, medical devices, and other health-related items directly from manufacturers, and then supplying these to healthcare institutions and pharmacies. The Pharmaceutical Manufacturing Business is dedicated to the research, development, production, and commercialization of prescription pharmaceuticals and diagnostic tools, with a particular emphasis on diabetes and kidney-related conditions. Through its Pharmacy Business segment, Suzuken offers services via family pharmacists, works to enhance the efficiency of local pharmacy operations, and provides educational support. The Healthcare-Related Services Business encompasses a variety of support functions, such as contract distribution for manufacturers, the distribution of orphan drugs, and nursing care services. This segment is also involved in the development, manufacturing, and sale of medical equipment, including electrocardiographs, blood pressure monitors, stethoscopes, general medical supplies, and health promotion devices. Furthermore, Suzuken Co., Ltd. publishes medical journals for healthcare professionals and collaborates with Bushu Pharmaceuticals Ltd. to provide specialized contract drug services. The company was established in 1932 and is headquartered in Nagoya, Japan.
SZUKF Stock 12 Month Forecast
Average Price Target
$40.64
▲(26.87% Upside)
Technical Analysis
Alfresa Holdings
―
Medipal Holdings
―
Sundrug Co
―
Sugi Holdings Co
―
KUSURI NO AOKI HOLDINGS CO.,LTD.
―
Ownership Overview
―
Insiders
5.57% Mutual Funds
― Other Institutional Investors
87.20% Public Companies and
Individual Investors










